{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T20:15:57Z","timestamp":1712348157358},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,29]],"date-time":"2012-07-29T00:00:00Z","timestamp":1343520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To quantify the contribution of locally implemented prevention programmes in contributing to reductions in treatment and care costs by averting HIV infections among those who inject drugs this study calculates net financial benefit of providing harm reduction programmes using information from services being implemented in Urumqi, Xinjiang Uighur Autonomous Region of China ( between 2005 and 2010).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Information was collected to assess cost of providing methadone treatment (MMT) and needle and syringe programmes (NSP). HIV incidence was estimated among people who inject drugs (PWID). HIV infections averted were calculated. Net benefit was assessed by estimating costs of providing prevention programmes and comparing these to the costs of providing care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>An estimated 5678 (range 3982\u20137599) HIV infections were averted between 2005 and 2010 and the net financial benefit of providing harm reduction programmes compared to treatment and care costs for HIV infections averted was USD 4.383 million during the same time period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These results demonstrate the net and accumulating benefit of investing in harm reduction programmes for PWID in Urumqi. The return on investment progressively increased during the time period studied and it is clear that these cost savings will continue to accrue with the continued implementation of HIV prevention interventions in the community that include harm reduction programmes targeted at PWID.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2458-12-572","type":"journal-article","created":{"date-parts":[[2012,7,29]],"date-time":"2012-07-29T08:13:41Z","timestamp":1343549621000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Net financial benefits of averting HIV infections among people who inject drugs in Urumqi, Xinjiang, Peoples Republic of China (2005\u20132010)"],"prefix":"10.1186","volume":"12","author":[{"given":"Mingjian J","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Yuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,29]]},"reference":[{"key":"4269_CR1","volume-title":"Return on investment in needle and syringe programs in Australia","author":"Commonwealth Department of Health and Aging (Australia)","year":"2002","unstructured":"Commonwealth Department of Health and Aging (Australia): Return on investment in needle and syringe programs in Australia. 2002, Publications Production Unit (Public Affairs, Public and Parliamentary Access Branch, Commonwealth Department of Health and Aging Australia), Australia"},{"key":"4269_CR2","volume-title":"Return on investment 2: Evaluating the cost effectiveness of needle and syringe programs in Australia","author":"Commonwealth Department of Health and Aging (Australia)","year":"2009","unstructured":"Commonwealth Department of Health and Aging (Australia): Return on investment 2: Evaluating the cost effectiveness of needle and syringe programs in Australia. 2009, Publications Production Unit (Public Affairs, Public and Parliamentary Access Branch, Commonwealth Department of Health and Aging Australia), Australia"},{"key":"4269_CR3","volume-title":"Cochrane Database Systematic Review","author":"L Gowing","year":"2011","unstructured":"Gowing L, Farrell MF, Borneman R, Sullivan LE, Ali R: Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Systematic Review. 2011, 10.1002\/14651858.CD004145.pub4. Issue 8. Art. No.: CD004145"},{"key":"4269_CR4","volume-title":"Estimated cost savings of reducing crime while in methadone treatment","author":"M Shanahan","year":"2007","unstructured":"Shanahan M, Hetherington K, Mattick RP, Weatherburn D: Estimated cost savings of reducing crime while in methadone treatment. 2007, National Drug and Alcohol Research Center, University of New South Wales, New South Wales, Technical Report No. 264. 2007"},{"key":"4269_CR5","volume-title":"Assessing the effectiveness of disease and injury prevention programs: costs and consequences. August 18 1995, 44. Morbidity and Mortality Weekly Report No RR-10","author":"USCDC","year":"1995","unstructured":"USCDC: Assessing the effectiveness of disease and injury prevention programs: costs and consequences. August 18 1995, 44. Morbidity and Mortality Weekly Report No RR-10. 1995, US Department of Health and Human Services Public Health Service"},{"key":"4269_CR6","first-page":"44","volume-title":"Health Statistics","author":"JQ Fang","year":"2003","unstructured":"Fang JQ: Health Statistics. 2003, Beijing People\u2019s Medical Publishing House, 44-5","edition":"5"},{"key":"4269_CR7","volume-title":"Progression and mortality of untreated HIV-positive individuals living in resource-limited settings: update of literature review and evidence synthesis","author":"M Zwahlen","year":"2006","unstructured":"Zwahlen M, Egger M: Progression and mortality of untreated HIV-positive individuals living in resource-limited settings: update of literature review and evidence synthesis. 2006, UNAIDS Obligation HQ\/05\/422204. http:\/\/data.unaids.org\/pub\/Periodical\/2006\/zwahlen_unaids_hq_05_422204_2007_en.pdf. Retrieved 2008-03-19"},{"issue":"4","key":"4269_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-151-4-200908180-00006","volume":"151","author":"F Zhang","year":"2009","unstructured":"Zhang F, Dou Z, Ma Y, et al: Five years outcomes of the china national free antiretroviral treatment program. An Int Medicine. 2009, 151 (4): 241-51. Aug 18, W-52","journal-title":"An Int Medicine"},{"issue":"9635","key":"4269_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","volume":"372","author":"Antiretroviral Therapy Cohort Collaboration","year":"2008","unstructured":"Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008, 372 (9635): 293-299.","journal-title":"Lancet"},{"key":"4269_CR10","first-page":"250","volume":"11","author":"L Zhang","year":"2011","unstructured":"Zhang L, Yap L, Zhuang X, Wu Z, Wilson D: Needle and Syringe Programs in Yunnan China yield health and financial returns. BMC publications. 2011, 11: 250-April 21","journal-title":"BMC publications"},{"issue":"5","key":"4269_CR11","doi-asserted-by":"publisher","first-page":"e5720","DOI":"10.1371\/journal.pone.0005720","volume":"4","author":"TB Hallett","year":"2011","unstructured":"Hallett TB, et al: Errors in BED derived estimates of HIV incidence will vary by time and age. PLoS One. 2011, 4 (5): e5720-101371\/journal.pone000572.","journal-title":"PLoS One"},{"key":"4269_CR12","volume-title":"Estimates Modeling and Projection Statement on use of BED-Assay for estimating HIV incidence for surveillance of epidemic monitoring","author":"UNAIDS Reference Group","year":"2006","unstructured":"UNAIDS Reference Group: Estimates Modeling and Projection Statement on use of BED-Assay for estimating HIV incidence for surveillance of epidemic monitoring. 2006, http:\/\/data.unaids.org\/pub\/EPISlides\/2006,"},{"issue":"4","key":"4269_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijid.2006.09.001","volume":"11","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Shan H, Trizzino J, Ruan Y, Beauchamp G, Masse B, Ma J, Rui B, Wang J, Liu M, Wang Y, He Y, Poundstone K, Jiang Y, Jackson JB, Shao Y: HIV incidence, retention rates and baseline predictors of HIV incidence and retention in prospective cohort studies of injecting drug users in Xinjiang, China. Int J Infect Dis. 2007, 11 (4): 318-323. 10.1016\/j.ijid.2006.09.001.","journal-title":"Int J Infect Dis"},{"key":"4269_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1477-7517-7-4","volume":"7","author":"J Li","year":"2010","unstructured":"Li J, Ha T, Zhan C, Liu H: The Chinese Government\u2019s response to drug use and HIV\/AIDS: A Review of the Policies and Programs. Harm Red J. 2010, 7: 4-10.1186\/1477-7517-7-4.","journal-title":"Harm Red J"},{"key":"4269_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1477-7517-3-4","volume":"3","author":"HZ Qian","year":"2006","unstructured":"Qian HZ, Schumacher JE, Chen HT, Ruan YH: Injecting Drug Use and HIV\/AIDS in China: Review of the current situation, prevention and policy implications. Harm Red J. 2006, 3: 4-10.1186\/1477-7517-3-4.","journal-title":"Harm Red J"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-12-572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2458-12-572\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-12-572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-12-572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:44:20Z","timestamp":1630525460000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-12-572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,29]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["4269"],"URL":"https:\/\/doi.org\/10.1186\/1471-2458-12-572","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,29]]},"assertion":[{"value":"28 March 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"572"}}